Market Overview

Array Biopharma Recoups Some Of Its Losses From Sharply Lower Open

Share:
Related ARRY
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs
The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut
Traders Are Confused- Cramer's Mad Money (12/10/18) (Seeking Alpha)

Array Biopharma Inc (NASDAQ: ARRY) shares are trading lower by $0.66 (7.2 percent) at $9.90 in Monday's session.

Before the open, the company announced its new drug application for its Binimetinib Monotherapy for the treatment of a rare skin cancer has been withdrawn from the FDA Division of Oncology Products. The company announced it will continue trials for the drug in combination with Encorafenib, with the Phase 3 results to be delivered in mid-2017.

After a much lower open, Array's stock reached $8.93 in the first minute of the session and began to rebound. That low coincides with a pair of lows from January 6 ($8.84) and January 9 ($8.88). So far, the ensuing rally has taken the issue right to the bottom end of Friday's range ($10.25).

At this time, the issue is attempting to avoid it first close under $10.00 since January 11, when it ended that session at $9.42.

Posted-In: Technicals Intraday Update Movers Trading Ideas

 

Related Articles (ARRY)

View Comments and Join the Discussion!

University Of Maryland's Non-Profit Initiative Is Changing Higher Education

Analyst Introduces Buy Rating On MeetMe, Sees Almost 50% Upside